Inceptua Group

inceptua.com

The Inceptua Group is a dynamic, enterprising, and future-oriented service provider operating within the clinical trial and unlicensed medicines supply chain at an international level. Our multinational team provide connections to an extensive global network, offering our clients customized solutions ranging from strategic planning and sourcing, clinical manufacturing and global depot solutions, right through to early access to unlicensed medicines.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

TEMPERATURE CONTROLLED PHARMACEUTICAL CONTAINERS MARKET GROWTH SALES REVENUE ANALYSIS 2019-2027

Daily Science | April 09, 2020

news image

In this report, the global Temperature Controlled Pharmaceutical Containers market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025. For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025. The Temperature Controlled Pharmaceutical Contain...

Read More

Pharma Tech

ZYNEX SUBMITS FDA APPLICATION FOR ITS NEXT GENERATION FLUID AND BLOOD VOLUME MONITOR

Zynex | January 04, 2022

news image

Zynex, Inc. an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced that it has submitted a 510(k) application to the U.S. Food and Drug Administration for the CM-1600, its next generation fluid monitoring system. "I am thrilled to announce that we have submitted a 510(k) premarket notification to the FDA for our CM...

Read More

Pharma Tech

KIOMED PHARMA AND HANSOH PHARMA ANNOUNCE LICENSE AGREEMENT FOR KIOMEDINEVSONE IN CHINA’S MAINLAND, MACAU AND TAIWAN

KiOmed Pharma and Hansoh Pharma | September 27, 2022

news image

KiOmed Pharma, a Belgian biotechnology company with a focus on the development, manufacture and distribution of safe and effective medical devices based on a medical-grade highly pure natural chitosan-derivative, and Hansoh Pharmaceutical Group Company Limited a leading biopharmaceutical company in Asia, today announced a license agreement for the development and commercialization of KiOmedinevsOne, a carboxymethyl chitosan injection that has been launched in Europe for the treatment of knee ost...

Read More

Business Insights

CITIUS PHARMACEUTICALS, INC. SECURES $3.6 MILLION THROUGH NEW JERSEY ECONOMIC DEVELOPMENT PROGRAM

Citius Pharmaceuticals, Inc. | November 22, 2022

news image

Citius Pharmaceuticals, Inc. a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that the Company has been selected to participate in New Jersey's Technology Business Tax Certificate Transfer Program, more commonly known as the Net Operating Loss Program, and will receive $3.6 million in non-dilutive capital through the New Jersey Economic Development Authority. Citius expects to receive the funds by late 2022 or early ...

Read More
news image

TEMPERATURE CONTROLLED PHARMACEUTICAL CONTAINERS MARKET GROWTH SALES REVENUE ANALYSIS 2019-2027

Daily Science | April 09, 2020

In this report, the global Temperature Controlled Pharmaceutical Containers market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025. For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025. The Temperature Controlled Pharmaceutical Contain...

Read More
news image

Pharma Tech

ZYNEX SUBMITS FDA APPLICATION FOR ITS NEXT GENERATION FLUID AND BLOOD VOLUME MONITOR

Zynex | January 04, 2022

Zynex, Inc. an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced that it has submitted a 510(k) application to the U.S. Food and Drug Administration for the CM-1600, its next generation fluid monitoring system. "I am thrilled to announce that we have submitted a 510(k) premarket notification to the FDA for our CM...

Read More
news image

Pharma Tech

KIOMED PHARMA AND HANSOH PHARMA ANNOUNCE LICENSE AGREEMENT FOR KIOMEDINEVSONE IN CHINA’S MAINLAND, MACAU AND TAIWAN

KiOmed Pharma and Hansoh Pharma | September 27, 2022

KiOmed Pharma, a Belgian biotechnology company with a focus on the development, manufacture and distribution of safe and effective medical devices based on a medical-grade highly pure natural chitosan-derivative, and Hansoh Pharmaceutical Group Company Limited a leading biopharmaceutical company in Asia, today announced a license agreement for the development and commercialization of KiOmedinevsOne, a carboxymethyl chitosan injection that has been launched in Europe for the treatment of knee ost...

Read More
news image

Business Insights

CITIUS PHARMACEUTICALS, INC. SECURES $3.6 MILLION THROUGH NEW JERSEY ECONOMIC DEVELOPMENT PROGRAM

Citius Pharmaceuticals, Inc. | November 22, 2022

Citius Pharmaceuticals, Inc. a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that the Company has been selected to participate in New Jersey's Technology Business Tax Certificate Transfer Program, more commonly known as the Net Operating Loss Program, and will receive $3.6 million in non-dilutive capital through the New Jersey Economic Development Authority. Citius expects to receive the funds by late 2022 or early ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us